EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer

Nature Cell Biology

Volumn 10, Issue 8, 2008, Pages 902-911

  Kolev, Vihren ^a   Mandinova, Anna ^a   Guinea Viniegra, Juan ^b   Hu, Bing ^c   Lefort, Karine ^c   Lambertini, Chiara ^c   Neel, Victor ^a   Dummer, Reinhard ^d   Wagner, Erwin F ^d   Dotto, Paolo G ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C JUN; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL GENETICS; CONTROLLED STUDY; EPIDERMIS; GENETIC SCREENING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN CARCINOGENESIS; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; KERATINOCYTES; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

MAMMALIA;

EID: 48649093670     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1750     Document Type: Article

References (44)

1. Lefort, K. & Dotto, G. P. Notch signaling in the integrated control of keratinocyte growth/differentiation and tumor suppression. Semin. Cancer Biol. 14, 374-386 (2004).
2. Lefort, K. et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKα kinases. Genes Dev. 21, 562-577 (2007).
3. Artavanis-Tsakonas, S., Rand, M. D. & Lake, R. J. Notch signaling: Cell fate control and signal integration in development. Science 284 770-776 (1999).
4. Bray, S. J. Notch signalling: A simple pathway becomes complex. Nature Rev. Mol. Cell Biol. 7, 678-689 (2006).
5. Yugawa, T. et al. Regulation of Notch1 gene expression by p53 in epithelial cells. Mol. Cell Biol. 27, 3732-3742 (2007).
6. Scaltriti, M. & Baselga, J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin. Cancer Res. 12, 5268-5272 (2006).
7. Jost, M., Kari, C. & Rodeck, U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur. J. Dermatol. 10 505-510 (2000).
8. Zenz, R. & Wagner, E. F. Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. Int. J. Biochem. Cell Biol. 38, 1043-1049 (2006).
9. Kalyankrishna, S. & Grandis, J. R. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol. 24, 2666-2672 (2006).
10. Citri, A. & Yarden, Y. EGF-ERBB signalling: Towards the systems level. Nature Rev. Mol. Cell Biol. 7, 505-516 (2006).
11. Lacouture, M. E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Rev. Cancer 6, 803-812 (2006).
12. Collins, I. & Workman, P. New approaches to molecular cancer therapeutics. Nature Chem. Biol. 2, 689-700 (2006).
13. Gong, Y. et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4, e294 (2007).
14. Scholl, F. A., Dumesic, P. A. & Khavari, P. A. Mek1 alters epidermal growth and differentiation. Cancer Res. 64, 6035-6040 (2004).
15. Friday, B. B. & Adjei, A. A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 14, 342-346 (2008).
16. Mandinova A. et al. The Fox03A gene is a key negative target of canonical Notch signaling in the keratinocyte UVB response. EMBO J. 27, 1243-1254 (2008).
17. Laptenko, O. & Prives, C. Transcriptional regulation by p53: One protein, many possibilities. Cell Death Differ. 13, 951-961 (2006).
18. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
19. Boggs. K. & Reisman, D. C/EBPβ participates in regulating transcription of the p53 gene in respoose to mitogen stimulation. J. Biol. Chem. 282, 7982-7990 (2007).
20. Bruno, T. et al. Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell 10, 473-486 (2006).
21. Phan, R. T. & Dalla-Favera, R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432, 635-639 (2004).
22. Schreiber, M. et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 13, 607-619 (1999).
23. Weng, A. P. et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol. Cell. Biol. 23, 655-664 (2003).
24. Miele, L., Miao, H. & Nickoloff, B. J. NOTCH signaling as a novel cancer therapeutic target. Curr. Cancer Drug Targets 6, 313-323 (2006).
25. Hasson, P. et al. EGFR signaling attenuates Groucho-dependent repression to antagonize Notch transcriptional output. Nature Genet. 37, 101-105 (2005).
26. Mizutani, K., Yoon, K., Dang, L., Tokunaga, A. & Gaiano, N. Differential Notch signalling distinguishes neural stem cells from intermediate progenitors. Nature 449, 351-355 (2007).
27. Schad K. et al. Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging. J. Clin. Oncol. 26, (May 20 suppl.) abstr 9075 (2008).
28. Sibilia, M. et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 102, 211-220 (2000).
29. Zenz, R. et al. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev. Cell 4, 879-889 (2003).
30. Hodge, D. R. et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 65, 4673-4682 (2005).
31. Kang, J. H. et al. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: Correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab. Invest. 81, 573-579 (2001).
32. Raman, V. et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405, 974-978 (2000).
33. Stuart, E. T., Haffner, R., Oren, M. & Gruss, P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J. 14, 5638-5645 (1995).
34. Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. & Strasser, A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 4 1681-1689 (2007).
35. Dotto, G. P. Signal transduction pathways controlling the switch between keratinocyte growth and differentiation. Crit. Rev. Oral Biol. Med. 10, 442-457 (1999).
36. Doroquez, D. B. & Rebay, I. Signal integration during development: mechanisms of EGFR and Notch pathway function and cross-talk. Crit. Rev. Biochem. Mol. Biol. 41, 339-385 (2006).
37. Tergaonkar, V. & Perkins, N. D. p53 and N F-κB crosstalk: IKKα tips the balance. Mol. Cell 26, 158-159 (2007).
38. Nguyen, B. C. et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 20, 1028-1042 (2006).
39. Dajee, M. et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421, 639-643 (2003).
40. Eferl, R. & Wagner, E. F. AP-1: A double-edged sword in tumorigenesis. Nature Rev. Cancer 3, 859-868 (2003).
41. Reuter, C. W., Morgan, M. A. & Eckardt, A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br. J. Cancer 96, 408-416 (2007).
42. Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471 (1998).
43. Musti, A. M., Treier, M. & Bohmann, D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275, 400-402 (1997).
44. Luetteke, N. C. et al. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 8, 399-413 (1994).